[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PL367777A1 - 5-ht receptor ligands and uses thereof - Google Patents

5-ht receptor ligands and uses thereof

Info

Publication number
PL367777A1
PL367777A1 PL02367777A PL36777702A PL367777A1 PL 367777 A1 PL367777 A1 PL 367777A1 PL 02367777 A PL02367777 A PL 02367777A PL 36777702 A PL36777702 A PL 36777702A PL 367777 A1 PL367777 A1 PL 367777A1
Authority
PL
Poland
Prior art keywords
receptor ligands
ligands
receptor
Prior art date
Application number
PL02367777A
Other languages
English (en)
Polish (pl)
Inventor
Yuan-Ching Phoebe Chiang
Paul Andrew Dasilva-Jardine
Ravi S. Garigipati
Angel Guzman-Perez
William Albert Novomisle
Willard Mckowan Welch
Kevin Kun-Chin Liu
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of PL367777A1 publication Critical patent/PL367777A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL02367777A 2001-06-21 2002-06-17 5-ht receptor ligands and uses thereof PL367777A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29995301P 2001-06-21 2001-06-21
PCT/IB2002/002293 WO2003000666A1 (fr) 2001-06-21 2002-06-17 Ligands des recepteurs 5-ht et leurs utilisations

Publications (1)

Publication Number Publication Date
PL367777A1 true PL367777A1 (en) 2005-03-07

Family

ID=23157027

Family Applications (2)

Application Number Title Priority Date Filing Date
PL02367777A PL367777A1 (en) 2001-06-21 2002-06-17 5-ht receptor ligands and uses thereof
PL02367746A PL367746A1 (en) 2001-06-21 2002-06-17 5-ht receptor ligands and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL02367746A PL367746A1 (en) 2001-06-21 2002-06-17 5-ht receptor ligands and uses thereof

Country Status (39)

Country Link
US (6) US6825198B2 (fr)
EP (2) EP1401819A1 (fr)
JP (2) JP2005501821A (fr)
KR (2) KR100566854B1 (fr)
CN (2) CN1630645A (fr)
AP (1) AP2002002561A0 (fr)
AR (1) AR036095A1 (fr)
AU (1) AU2002309173B2 (fr)
BG (2) BG108491A (fr)
BR (2) BR0210503A (fr)
CA (2) CA2450491A1 (fr)
CR (1) CR7168A (fr)
CZ (2) CZ20033431A3 (fr)
DO (1) DOP2002000412A (fr)
EA (2) EA007183B1 (fr)
EC (2) ECSP034881A (fr)
EE (2) EE200400026A (fr)
GE (1) GEP20053655B (fr)
GT (1) GT200200120A (fr)
HR (1) HRP20031042A2 (fr)
HU (2) HUP0400251A3 (fr)
IL (2) IL158807A0 (fr)
IS (2) IS7040A (fr)
MA (2) MA27035A1 (fr)
MX (2) MXPA03011941A (fr)
NO (2) NO20035698L (fr)
NZ (1) NZ529542A (fr)
OA (2) OA12629A (fr)
PA (1) PA8548901A1 (fr)
PE (1) PE20030268A1 (fr)
PL (2) PL367777A1 (fr)
SK (2) SK15672003A3 (fr)
SV (1) SV2003001102A (fr)
TN (2) TNSN03142A1 (fr)
UA (1) UA74443C2 (fr)
UY (1) UY27343A1 (fr)
WO (2) WO2003000663A1 (fr)
YU (1) YU95303A (fr)
ZA (2) ZA200308842B (fr)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7655658B2 (en) * 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
US7732451B2 (en) * 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
AU2002331064B2 (en) * 2001-08-10 2007-08-23 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
US7456184B2 (en) * 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
US7354923B2 (en) * 2001-08-10 2008-04-08 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US6953787B2 (en) 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators
US7226925B2 (en) 2002-06-19 2007-06-05 Biovitrum Ab Compounds, their use and preparation
EA008148B1 (ru) 2002-06-19 2007-04-27 Биовитрум Аб Новые соединения, их применение и получение
GEP20084540B (en) 2003-01-14 2008-11-25 Arena Pharm Inc 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CA2514220C (fr) * 2003-01-29 2012-02-28 Pharmagene Laboratories Limited Antagonistes aux recepteurs ep4
JP4695588B2 (ja) * 2003-02-26 2011-06-08 スージェン， インク． プロテインキナーゼ阻害剤としてのアミノヘテロアリール化合物
US20040235856A1 (en) * 2003-04-25 2004-11-25 Pfizer Inc Treatment of incontinence
CL2004000826A1 (es) 2003-04-25 2005-03-04 Pfizer Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
US20080146583A1 (en) * 2003-05-15 2008-06-19 Pfizer Inc Treatment of Incontinence
US7968548B2 (en) 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
EP2332920A3 (fr) 2003-06-17 2011-12-21 Arena Pharmaceuticals, Inc. Procédés de préparation de 3-benzazepines
EP2332921B1 (fr) 2003-06-17 2016-03-02 Arena Pharmaceuticals, Inc. 8-Chloro-1 -methyl-2,3,4,5-tetrahydro-1 H-3benzazapine Hydrochloride
MXPA05013365A (es) * 2003-06-20 2006-04-05 Arena Pharm Inc Derivados de n-fenil-piperazina y metodos para profilaxis o tratamiento de enfermedades asociadas con el receptor 5ht2c.
CN102417508A (zh) 2003-07-14 2012-04-18 艾尼纳制药公司 作为新陈代谢调节剂的稠合芳基和杂芳基衍生物以及预防和治疗与其相关的病症
US7390907B2 (en) 2003-09-30 2008-06-24 Amgen Inc. Vanilloid receptor ligands and their use in treatments
WO2005053688A1 (fr) 2003-11-26 2005-06-16 Alcon, Inc. Furo[2,3-g] indazoles substitues destines au traitement du glaucome
US7338972B1 (en) 2003-12-15 2008-03-04 Alcon, Inc. Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
US20080194574A1 (en) * 2003-12-16 2008-08-14 Axxima Pharmaceuticals Ag Pyrazine Derivatives As Effective Compounds Against Infectious Diseases
EP1734963A4 (fr) 2004-04-02 2008-06-18 Merck & Co Inc Methode destinee a traiter des hommes presentant des troubles metaboliques et anthropometriques
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
SI1756084T1 (sl) * 2004-06-04 2009-04-30 Arena Pharm Inc Substituirani arilni in heteroarilni derivati kot modulatorji metabolizma ter profilaksa in zdravljenje motenj v zvezi s tem
EP2400300A1 (fr) 2004-08-25 2011-12-28 Takeda Pharmaceutical Company Limited Procédé de sélection d'agents préventifs/remèdes pour l'incontinence de stress
US8114502B2 (en) * 2004-09-02 2012-02-14 3M Innovative Properties Company Substrates with multiple images
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
AU2005305036B2 (en) * 2004-11-01 2011-03-10 Amylin Pharmaceuticals, Llc Treatment of obesity and related disorders
BRPI0518241A (pt) * 2004-11-01 2008-04-22 Amylin Pharmaceuticals Inc métodos para tratar obesidade e doenças e distúrbios relacionados à obesidade
AR051946A1 (es) * 2004-11-05 2007-02-21 Wyeth Corp Formulaciones de derivados de [1,4] diazepina [6,7,1-ij] quinolina
RU2007122485A (ru) 2004-11-17 2008-12-27 Мийкана Терапьютикс Ингибиторы киназы
CA2594987A1 (fr) * 2004-12-14 2006-06-22 Shionogi & Co., Ltd. Agent therapeutique pour la constipation
PL1838677T3 (pl) 2004-12-21 2010-02-26 Arena Pharm Inc Krystaliczne postacie agonisty chlorowodorku (R)-8-chloro-1-metylo-2,3,4,5-tetrahydro-1H-3-benzazepiny
CA2588941A1 (fr) * 2004-12-23 2006-07-06 Arena Pharmaceuticals, Inc. Compositions renfermant un modulateur des recepteurs 5ht2c et procedes d'utilisation correspondants
RU2440996C2 (ru) * 2005-01-25 2012-01-27 Галенеа Корп. Замещенные ариламины и их применение в качестве модуляторов 5-ht6-рецептора
KR100894006B1 (ko) * 2005-03-31 2009-04-17 화이자 프로덕츠 인코포레이티드 사이클로펜타피리딘 및 테트라하이드로퀴놀린 유도체
US7594976B2 (en) * 2005-05-13 2009-09-29 3M Innovative Properties Company Methods of manufacturing substrates
JP2009502961A (ja) 2005-07-29 2009-01-29 コンサート ファーマシューティカルズ インコーポレイテッド 新規な医薬組成物
ES2535854T3 (es) * 2005-09-30 2015-05-18 Miikana Therapeutics, Inc. Compuestos de pirazol sustituidos
BRPI0619424B1 (pt) * 2005-12-05 2022-02-08 Pfizer Products Inc Uso de inibidores c-met/hgfrs para a fabricação de medicamentos
CN101326175B (zh) * 2005-12-05 2012-07-18 辉瑞产品公司 C-met/hgfr抑制剂的多晶型物
KR20080081321A (ko) * 2005-12-21 2008-09-09 쉐링 코포레이션 Ｈ3 길항제/역 작용제 및 식욕 억제제의 조합물
CA2646044A1 (fr) 2006-04-03 2007-10-25 Arena Pharmaceuticals, Inc. Procedes de preparation de 8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine et produits intermediaires associes
EP2018863B9 (fr) 2006-05-16 2015-02-18 Takeda Pharmaceutical Company Limited Composé hétérocyclique fusionné et utilisation
BRPI0711740A2 (pt) * 2006-05-30 2011-12-06 Hoffmann La Roche compostos, processo para a sua manufatura,composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3, método para o tratamento ou prevenção de obesidade, de diabetes do tipo ii, e uso dos compostos na manufatura de medicamentos
KR20090029299A (ko) * 2006-07-14 2009-03-20 화이자 프로덕츠 인코포레이티드 (7ｓ)-7-[(5-플루오로-2-메틸-벤질)옥시]-2-[(2ｒ)-2-메틸피페라진-1-일]-6,7-다이하이드로-5ｈ-사이클로펜타[ｂ]피리딘의 타르트레이트 염
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
CA2669311C (fr) 2006-11-13 2011-09-20 Pfizer Products Inc. Derives diaryle, dipyridinyle et aryl-pyridinyle et leurs utilisations
SI2848610T1 (en) * 2006-11-15 2018-02-28 Ym Biosciences Australia Pty Ltd Inhibitors of kinase activity
ES2522587T3 (es) 2006-12-05 2014-11-17 Arena Pharmaceuticals, Inc. Procesos para preparar (R)-8-cloro-1-metil-2,3,4,5-tetrahidro-1H-3-benzacepina e intermedios de la misma
SG178716A1 (en) 2007-01-16 2012-03-29 Ipintl Llc Novel composition for treating metabolic syndrome
US20080220104A1 (en) * 2007-03-08 2008-09-11 Cappello John V Compositions for producing satiety
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
JP5546451B2 (ja) 2007-06-04 2014-07-09 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸の障害、炎症、癌および他の障害の処置に有用なグアニル酸シクラーゼのアゴニスト
AU2008262291A1 (en) * 2007-06-11 2008-12-18 Miikana Therapeutics, Inc. Substituted pyrazole compounds
US20100266504A1 (en) 2007-11-15 2010-10-21 Takahiro Matsumoto Condensed pyridine derivative and use thereof
EP2288585A1 (fr) * 2008-03-04 2011-03-02 Arena Pharmaceuticals, Inc. Procédés de préparation d'intermédiaires se rapportant à l'agoniste 5-ht2c (r)-8-chloro-1-méthyl-2,3,4,5-tétrahydro-1h-3-benzazepine
EP2810951B1 (fr) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
CN102118969B (zh) 2008-06-12 2017-03-08 詹森药业有限公司 组胺h4受体的二氨基吡啶、二氨基嘧啶和二氨基哒嗪调节剂
WO2009154739A2 (fr) * 2008-06-17 2009-12-23 Duke University Modulateurs du récepteur smoothened
EP3241839B1 (fr) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
CN102271509A (zh) 2008-10-31 2011-12-07 默沙东公司 用于抗糖尿病药的新型环苯并咪唑衍生物
CA2743489A1 (fr) 2008-11-17 2010-05-20 Merck Sharp & Dohme Corp. Amines bicycliques substituees pour le traitement du diabete
US8952197B2 (en) 2009-06-18 2015-02-10 Arena Pharmaceuticals, Inc. Processes for the preparation of 5-HT2C receptor agonists
CN102803247B (zh) * 2009-06-26 2014-11-05 赛诺菲 组胺h3受体拮抗剂的新颖富马酸盐
CA2768577A1 (fr) 2009-07-23 2011-01-27 Schering Corporation Composes d?oxazepine benzofusionnes en tant qu?inhibiteurs de la coenzyme-stearoyle a delta-9 desaturase
WO2011011506A1 (fr) 2009-07-23 2011-01-27 Schering Corporation Composés oxazépine spirocyclique en tant qu'inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase
EP2510949A4 (fr) 2009-12-11 2013-11-13 Astellas Pharma Inc Agent thérapeutique pour la fibromyalgie
CA2786314A1 (fr) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Nouveaux derives benzimidazole cycliques utiles comme agents antidiabetiques
WO2011137024A1 (fr) 2010-04-26 2011-11-03 Merck Sharp & Dohme Corp. Nouveaux inhibiteurs de spiropipéridine prolylcarboxypeptidase
EP2568812B1 (fr) 2010-05-11 2016-10-26 Merck Sharp & Dohme Corp. Inhibiteurs inédits de la prolylcarboxypeptidase
WO2011153206A1 (fr) 2010-06-02 2011-12-08 Arena Pharmaceuticals, Inc. Procédés pour la préparation d'agonistes du récepteur 5-ht2c
US9006268B2 (en) 2010-06-11 2015-04-14 Merck Sharp & Dohme Corp. Prolylcarboxypeptidase inhibitors
EP3613504A1 (fr) * 2010-06-23 2020-02-26 Johnson Matthey Public Limited Company Complexes pi-allyl palladium et pi-allyl nickel et utilisation comme catalyseurs dans les reactions de couplage carbone-carbone et carbone-azote
EP2611449A1 (fr) 2010-09-01 2013-07-10 Arena Pharmaceuticals, Inc. Administration de lorcasérine à des individus présentant une insuffisance rénale
SG188361A1 (en) 2010-09-01 2013-04-30 Arena Pharm Inc Non-hygroscopic salts of 5-ht2c agonists
US20130315994A1 (en) 2010-09-01 2013-11-28 Zezhi Jesse Shao Modified-release dosage forms of 5-ht2c agonists useful for weight management
WO2012030938A1 (fr) 2010-09-01 2012-03-08 Arena Pharmaceuticals, Inc. Sels de lorcasérine dotés d'acides optiquement actifs
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
PE20131371A1 (es) 2010-09-22 2013-11-25 Arena Pharm Inc Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con este
CN103476258B (zh) 2011-02-25 2017-04-26 默沙东公司 用作抗糖尿病药剂的新的环状氮杂苯并咪唑衍生物
MX336155B (es) * 2011-02-25 2016-01-07 Yuhan Corp Derivados de diaminopirimidina y procesos para su preparacion.
MX2014014308A (es) * 2012-05-30 2015-02-12 Hoffmann La Roche Pirrolidino heterociclos.
CA2880901A1 (fr) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Composes tricycliques antidiabetiques
CA2886875A1 (fr) 2012-10-09 2014-04-17 Arena Pharmaceuticals, Inc. Procede de gestion du poids
CA2897651C (fr) 2013-01-10 2021-09-21 Pulmokine, Inc. Inhibiteurs de kinase non selectifs
RU2015140066A (ru) 2013-02-22 2017-03-30 Мерк Шарп И Доум Корп. Противодиабетические бициклические соединения
EP2970119B1 (fr) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Nouveaux dérivés d'indole utiles en tant qu'agents antidiabétiques
EP2968439A2 (fr) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions utiles pour le traitement de troubles gastro-intestinaux
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
EP4424697A2 (fr) 2013-06-05 2024-09-04 Bausch Health Ireland Limited Agonistes ultra-purs de guanylate cyclase c, leur procédé de fabrication et d'utilisation
WO2015051496A1 (fr) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Composés tricycliques antidiabétiques
US9925184B2 (en) 2013-10-11 2018-03-27 Pulmokine, Inc. Spray-dry formulations
WO2015066344A1 (fr) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. Agonistes du récepteur 5-ht2c et compositions et procédés d'utilisation
NZ771435A (en) 2015-01-06 2024-08-30 Arena Pharm Inc Methods of treating conditions related to the s1p1 receptor
MA42807A (fr) 2015-06-22 2018-07-25 Arena Pharm Inc Sel l-arginine cristallin d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclo-penta[b]indol-3-yl)acétique (composé 1) pour une utilisation dans des troubles associés au récepteur de s1p1
RU2763525C2 (ru) 2016-10-27 2021-12-30 Пульмокин, Инк. Комбинированная терапия для лечения легочной гипертензии
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
US10968232B2 (en) 2016-12-20 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
MA47504A (fr) 2017-02-16 2019-12-25 Arena Pharm Inc Composés et méthodes de traitement de l'angiocholite biliaire primitive
US20210052600A1 (en) 2017-12-27 2021-02-25 Takeda Pharmaceutical Company Limited Therapeutic agents for stress urinary incontinence and incotinence of feces
WO2020181194A1 (fr) * 2019-03-07 2020-09-10 University Of Padova Compositions et méthodes d'utilisation comprenant des substances ayant des actions de plasticité neurale administrées à des doses et formulations non psychédéliques/psychotomimétiques
CN111704582B (zh) * 2020-06-23 2021-06-11 杭州煌森生物科技有限公司 一种法匹拉韦及其衍生物的制备方法
CN115618396B (zh) * 2022-11-28 2023-04-07 云账户技术(天津)有限公司 一种数据的加密方法及装置

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL127996C (fr) * 1963-11-19
US3980781A (en) * 1966-03-31 1976-09-14 Imperial Chemical Industries Limited Fungicidal composition and method containing 2-amino-pyrimidines
GB1165283A (en) * 1967-01-17 1969-09-24 Science Union & Cie New Purine Derivatives and processes for prepararing them
FR2281117A2 (fr) 1974-08-09 1976-03-05 Ugine Kuhlmann Nouvelles piperazino-pyrimidines utilisables comme medicaments
US4166852A (en) * 1974-08-09 1979-09-04 Produits Chimiques Ugine Kuhlmann Piperazino-pyrimidines and their use as spasmolytic agents
US4081542A (en) * 1975-04-21 1978-03-28 Merck & Co., Inc. Piperazinylpyrazines
DK143899C (da) * 1975-04-21 1982-04-13 Merck & Co Inc Analogifremgangsmaade til fremstilling af piperazinylpyrazinderivater
FR2311776A1 (fr) * 1975-05-23 1976-12-17 Sogeras Diamino-2,4 bromo-5 chloro-6 pyrimidines et procede pour leur preparation
FI70411C (fi) * 1980-12-29 1986-09-19 Pfizer Foerfarande foer framstaellning av nya antihypertensiva 4-amino-6,7-dimetoxi-2-piperazinokinazolin derivat
HU206337B (en) * 1988-12-29 1992-10-28 Mitsui Petrochemical Ind Process for producing pyrimidine derivatives and pharmaceutical compositions
DE3905364A1 (de) * 1989-02-22 1990-08-23 Hoechst Ag Substituierte pyrimidin-derivate, verfahren zu ihrer herstellung und ihre verwendung als tool
GB9012592D0 (en) 1990-06-06 1990-07-25 Smithkline Beecham Intercredit Compounds
JPH0665203A (ja) * 1992-06-25 1994-03-08 Elf Sanofi ピペラジンのヘテロ環誘導体
KR950703539A (ko) * 1992-09-28 1995-09-20 알렌 제이. 스피겔 당뇨병 합병증 치료용 치환된 피리미딘(substituted pyrimidines for control or diabetic complications)
RU2153494C2 (ru) * 1993-10-12 2000-07-27 Дзе Дюпон Мерк Фармасьютикал Компани 1-n-алкил-n-арилпиримидинамины, способ лечения заболеваний, фармацевтическая композиция
KR960704855A (ko) * 1993-10-12 1996-10-09 돈 엠. 커. 1n-알킬-n-아릴피리미딘아민 및 이들의 유도체 (1n-alkyl-n-arylpyrimidinamines and derivatives thereof)
US5419301A (en) * 1994-04-14 1995-05-30 Ford Motor Company Adaptive control of camless valvetrain
EP0826674A4 (fr) 1995-04-03 1998-07-08 Sumitomo Pharma Nouveaux derives de pyrimidine efficaces en tant que medicament psychotrope et leur procede de fabrication
US5795905A (en) 1995-06-06 1998-08-18 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
EP0791355B1 (fr) * 1996-02-29 2002-04-17 Pfizer Inc. Utilisation d'inhibiteurs de deshydrogenase de sorbitol pour reduire des lésions tissulaires associés avec l'ischemie
US6326368B1 (en) * 1996-03-27 2001-12-04 Dupont Pharmaceuticals Company Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof
TW440563B (en) * 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
KR100239800B1 (ko) * 1996-11-28 2000-03-02 손경식 4,5-디아미노 피리미딘 유도체 및 이의 제조방법
DE19710435A1 (de) * 1997-03-13 1998-09-17 Hoechst Ag Verwendung von Pyrimidinderivaten zur Prävention von Krebs allein oder in Kombination mit anderen therapeutischen Maßnahmen
US6440965B1 (en) * 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
AU1738900A (en) 1998-11-19 2000-06-05 Nortran Pharmaceuticals Inc. Serotonin ligands as pro-erectile compounds
GB9902047D0 (en) 1999-01-29 1999-03-17 Cerebrus Ltd Chemical compounds XI
MXPA01011905A (es) 1999-05-21 2004-03-19 Biovitrum Ab Compuestos novedosos, su uso y preparacion.
SE0002754D0 (sv) 2000-07-21 2000-07-21 Pharmacia & Upjohn Ab New pharmaceutical combination formulation and method of treatment with the combination
SE0004245D0 (sv) * 2000-11-20 2000-11-20 Pharmacia Ab Novel compounds and their use
JP4387103B2 (ja) * 2000-11-20 2009-12-16 ビオヴィトルム・アクチボラゲット（プブリクト） セロトニン５ｈｔ−２レセプターのアゴニストまたはアンタゴニストとしてのピペラジニルピラジン化合物
CN1227237C (zh) 2000-11-20 2005-11-16 比奥维特罗姆股份公司 作为五羟色胺5－ht2受体拮抗剂的哌嗪基吡嗪化合物

Also Published As

Publication number Publication date
AP2002002561A0 (en) 2002-06-30
TNSN03142A1 (fr) 2005-12-23
HRP20031042A2 (en) 2005-10-31
MXPA03011940A (es) 2004-03-26
OA12621A (en) 2006-06-12
EA200301215A1 (ru) 2004-04-29
US6894050B2 (en) 2005-05-17
US20050032809A1 (en) 2005-02-10
WO2003000663A1 (fr) 2003-01-03
US6995159B2 (en) 2006-02-07
IL158807A0 (en) 2004-05-12
US20030125334A1 (en) 2003-07-03
ZA200308842B (en) 2004-11-23
PE20030268A1 (es) 2003-03-19
AR036095A1 (es) 2004-08-11
NO20035698D0 (no) 2003-12-19
US20050090503A1 (en) 2005-04-28
ZA200308843B (en) 2004-11-23
KR20040010765A (ko) 2004-01-31
US20050054656A1 (en) 2005-03-10
NZ529542A (en) 2005-05-27
TNSN03143A1 (fr) 2005-12-23
BR0210471A (pt) 2004-08-10
SK15712003A3 (sk) 2004-06-08
HUP0400249A3 (en) 2009-01-28
YU95303A (sh) 2006-08-17
ECSP034881A (es) 2004-01-28
MXPA03011941A (es) 2004-03-26
GEP20053655B (en) 2005-11-10
IS7041A (is) 2003-11-17
CA2450491A1 (fr) 2003-01-03
KR100566854B1 (ko) 2006-04-03
CZ20033508A3 (en) 2004-05-12
UY27343A1 (es) 2003-02-28
US20050020604A1 (en) 2005-01-27
NO20035697D0 (no) 2003-12-19
GT200200120A (es) 2003-02-13
CN1745074A (zh) 2006-03-08
KR20040010767A (ko) 2004-01-31
AU2002309173B2 (en) 2007-04-26
IS7040A (is) 2003-11-17
UA74443C2 (uk) 2005-12-15
HUP0400251A2 (hu) 2004-08-30
DOP2002000412A (es) 2002-12-30
HUP0400251A3 (en) 2006-02-28
WO2003000666A1 (fr) 2003-01-03
EE200400026A (et) 2004-06-15
CZ20033431A3 (en) 2004-07-14
SK15672003A3 (sk) 2004-05-04
SV2003001102A (es) 2003-03-18
US20030105106A1 (en) 2003-06-05
MA27035A1 (fr) 2004-12-20
EA200301213A1 (ru) 2004-06-24
BG108495A (en) 2004-08-31
JP2004534823A (ja) 2004-11-18
EA007183B1 (ru) 2006-08-25
JP2005501821A (ja) 2005-01-20
BG108491A (en) 2005-01-31
ECSP034884A (es) 2004-01-28
EP1401820A1 (fr) 2004-03-31
IL158808A0 (en) 2004-05-12
EP1401819A1 (fr) 2004-03-31
US6825198B2 (en) 2004-11-30
PA8548901A1 (es) 2003-02-14
CN1630645A (zh) 2005-06-22
BR0210503A (pt) 2004-05-18
EE200400025A (et) 2004-06-15
PL367746A1 (en) 2005-03-07
MA27036A1 (fr) 2004-12-20
CA2455292A1 (fr) 2003-01-03
NO20035698L (no) 2004-02-17
CR7168A (es) 2004-02-23
HUP0400249A2 (hu) 2004-08-30
OA12629A (en) 2006-06-14

Similar Documents

Publication Publication Date Title
IL158807A0 (en) 5-ht receptor ligands and uses thereof
ZA200507350B (en) Cannabinoid receptor ligands and uses thereof
IL172026A0 (en) Cannabinoid receptor ligands and uses thereof
IL161439A0 (en) Cannabinoid receptor ligands
IL156829A0 (en) Cannabinoid receptor ligands
EP1393657A4 (fr) Siege
IL157969A0 (en) Melanocortin receptor ligands
GB0214835D0 (en) Suspended seat
IL173265A0 (en) Imidazo-pyrimidines and triazolo-pyrimidines: benzodiazcpine receptor ligands
PL354799A1 (en) Complex containing ocif and polysaccharide
AU2002346507A8 (en) Benzazepine derivatives and their use as 5-ht ligands
GB0106434D0 (en) Novel estrogwen receptor ligands and methods II
GB2378645B (en) Seat
GB0100163D0 (en) Novel estrogen receptor ligands and methods
GB0124346D0 (en) Receptor and its use
GB0125183D0 (en) Receptor
GB0114929D0 (en) Receptor
GB0111959D0 (en) Receptor
GB0128161D0 (en) Receptor protein
GB0100164D0 (en) Novel estrogen receptor ligands and methods II
AU146542S (en) Hanging seat
GB0211205D0 (en) Receptor and ligand
GB2378644B (en) Seat
CA96919S (en) Spout
GB2371220B (en) Hanger

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)